Diabetes treatment and wound care biologics markets projected to grow

The global diabetes management market is experiencing significant growth, driven by rising prevalence rates and innovations in treatment. The diabetes therapeutics market is projected to grow from $7.76 billion in 2026 to $95.13 billion by 2030, with a compound annual growth rate (CAGR) of 5.2%. Key drivers include the development of new GLP-1 receptor agonists, SGLT-2 inhibitors, and fixed-dose combination therapies, such as Sanofi’s Soliqua, which aims to improve patient adherence by combining insulin glargine and lixisenatide.

Parallel to pharmaceutical advancements, the wound care biologics market is expanding due to the increasing need for treating chronic wounds associated with diabetes. This market is expected to reach $2.4 billion by 2026 and $3.19 billion by 2030. Innovations in bioengineered synthetic polymer matrices, biological skin substitutes, and regenerative medicine are enhancing healing outcomes for ulcers, surgical wounds, and burns. The integration of digital wound monitoring and personalized treatment approaches is further accelerating market momentum as healthcare systems seek more effective solutions for complex, chronic wound management.